Evotec Future Growth
Future criteria checks 3/6
Evotec is forecast to grow earnings and revenue by 72.7% and 6.6% per annum respectively. EPS is expected to grow by 75.9% per annum. Return on equity is forecast to be 7.3% in 3 years.
Key information
72.7%
Earnings growth rate
75.87%
EPS growth rate
| Life Sciences earnings growth | 20.2% |
| Revenue growth rate | 6.6% |
| Future return on equity | 7.26% |
| Analyst coverage | Good |
| Last updated | 11 May 2026 |
Recent future growth updates
Recent updates
Narrative Update • May 23
EVT: Future Milestone And Royalty Stream Will Support Earnings Upside
Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).
Narrative Update • May 04
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
Narrative Update • Apr 19
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Narrative Update • Apr 05
EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).Narrative Update • Mar 21
EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.Narrative Update • Mar 07
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.Narrative Update • Feb 20
EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.Narrative Update • Feb 06
EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).Narrative Update • Jan 22
EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.Narrative Update • Jan 07
EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.Narrative Update • Dec 17
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.Narrative Update • Dec 03
EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Narrative Update • Aug 21
Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
New Narrative • Apr 30
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Analysis Article • Nov 10
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...Analysis Article • Nov 05
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Analysis Article • Aug 17
Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Analysis Article • Aug 08
Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...Analysis Article • Aug 03
We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Apr 10
Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...Analysis Article • Mar 05
These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Jan 09
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price
With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 897 | 45 | 31 | 138 | 7 |
| 12/31/2027 | 818 | -30 | -41 | 67 | 10 |
| 12/31/2026 | 738 | -125 | -143 | -8 | 8 |
| 3/31/2026 | 745 | -194 | -53 | 19 | N/A |
| 12/31/2025 | 788 | -104 | -92 | -9 | N/A |
| 9/30/2025 | 756 | -159 | -91 | 1 | N/A |
| 6/30/2025 | 777 | -156 | 12 | 112 | N/A |
| 3/31/2025 | 788 | -207 | -76 | 35 | N/A |
| 12/31/2024 | 797 | -196 | -114 | 18 | N/A |
| 9/30/2024 | 777 | -171 | -209 | -36 | N/A |
| 6/30/2024 | 788 | -171 | -246 | -55 | N/A |
| 3/31/2024 | 777 | -91 | -228 | -12 | N/A |
| 12/31/2023 | 781 | -84 | -180 | 36 | N/A |
| 9/30/2023 | 821 | -95 | -188 | -14 | N/A |
| 6/30/2023 | 798 | -103 | -246 | -42 | N/A |
| 3/31/2023 | 800 | -116 | -39 | 143 | N/A |
| 12/31/2022 | 751 | -176 | 24 | 206 | N/A |
| 9/30/2022 | 698 | -180 | 121 | 297 | N/A |
| 6/30/2022 | 684 | 2 | 194 | 322 | N/A |
| 3/31/2022 | 650 | 90 | 58 | 183 | N/A |
| 12/31/2021 | 618 | 216 | 3 | 122 | N/A |
| 9/30/2021 | 571 | 247 | -58 | 86 | N/A |
| 6/30/2021 | 541 | 112 | -50 | 93 | N/A |
| 3/31/2021 | 515 | 42 | -99 | 20 | N/A |
| 12/31/2020 | 501 | 6 | -54 | 45 | N/A |
| 9/30/2020 | 485 | 14 | -4 | 62 | N/A |
| 6/30/2020 | 470 | 35 | 0 | 46 | N/A |
| 3/31/2020 | 462 | 42 | 43 | 82 | N/A |
| 12/31/2019 | 446 | 38 | N/A | 42 | N/A |
| 9/30/2019 | 419 | 61 | N/A | 29 | N/A |
| 6/30/2019 | 404 | 77 | N/A | 74 | N/A |
| 3/31/2019 | 398 | 94 | N/A | 139 | N/A |
| 12/31/2018 | 375 | 84 | N/A | 156 | N/A |
| 9/30/2018 | 370 | 63 | N/A | 135 | N/A |
| 6/30/2018 | 338 | 31 | N/A | 80 | N/A |
| 3/31/2018 | 294 | 20 | N/A | 19 | N/A |
| 12/31/2017 | 264 | 23 | N/A | 11 | N/A |
| 9/30/2017 | 215 | 28 | N/A | 64 | N/A |
| 6/30/2017 | 193 | 35 | N/A | 73 | N/A |
| 3/31/2017 | 178 | 36 | N/A | 74 | N/A |
| 12/31/2016 | 165 | 28 | N/A | 67 | N/A |
| 9/30/2016 | 160 | 18 | N/A | 5 | N/A |
| 6/30/2016 | 148 | 6 | N/A | -6 | N/A |
| 3/31/2016 | 144 | 17 | N/A | -2 | N/A |
| 12/31/2015 | 128 | 17 | N/A | 16 | N/A |
| 9/30/2015 | 119 | 12 | N/A | 19 | N/A |
| 6/30/2015 | 104 | 11 | N/A | 23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: EVT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EVT is expected to become profitable in the next 3 years.
Revenue vs Market: EVT's revenue (6.6% per year) is forecast to grow slower than the German market (6.8% per year).
High Growth Revenue: EVT's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EVT's Return on Equity is forecast to be low in 3 years time (7.3%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 05:32 |
| End of Day Share Price | 2026/05/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evotec SE is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |